Filing Flows › Biotricity (BTCY) › Q4 FY25
Biotricity (BTCY) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jul 15, 2025
Biotricity (BTCY) reported revenue of $3.7M for the fourth quarter fiscal 2025 (Q4 FY25), +16% from a year earlier and +2% from the quarter before. Operating margin was -23.1%, net loss $1.9M (52.3% of revenue).
Biotricity, Q4 FY25: revenue $3.7M (+16% year over year), operating margin -23.1%, net loss $1.9M, operating cash flow −$401K. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | +2% | +16% |
| Operating profit | −$855K | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$401K | — | — |
What changed
Revenue was $3.7M in Q4 FY25, up 16% year over year and up 2% from the previous quarter. Technology Fees was the largest line at 84% of revenue.
Gross margin was 80.4%, up 8.9 points from a year earlier. Operating costs exceeded revenue by $855K, an operating margin of -23.1%. Operating expenses fell 28% while revenue rose 16%. The quarter ended with a net loss of $1.9M, wider than the previous quarter's $1.2M loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$401K. Non-cash charges added back $1K of depreciation and $1.3M of share-based compensation. Working capital and other items added $245K.
Questions
What was Biotricity's revenue in the fourth quarter fiscal 2025?
Biotricity (BTCY) reported revenue of $3.7M for the fourth quarter fiscal 2025 (Q4 FY25), +16% from a year earlier and +2% from the quarter before.
Was Biotricity profitable in the fourth quarter fiscal 2025?
Operating loss was $855K (-23.1% of revenue) and net loss $1.9M.
Source: Biotricity 10-K on SEC EDGAR.